Geared towards low-income patients with uncontrolled hypertension, a multifaceted, team-based implementation strategy for ...
MedPage Today on MSN
Many Older Patients Can Ditch Common Thyroid Drug, Study Suggests
Experts call for better guidance on levothyroxine initiation, deprescribing ...
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today ...
In an interview with Targeted Oncology, Pavlos Msaouel, MD, PhD, at The University of Texas MD Anderson Cancer Center outlines the key clinical red flags that should prompt community oncologists to ...
Reusable catheter strategies may be as safe as single-use devices for preventing UTIs, but questions remain about their practical use.
Ohio company’s RESTORE trial shows major symptom relief using a wearable headset — with zero serious side effects ...
Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...
First Olmsted syndrome patient dosed in global Phase 1b studyCompany now operating under its new name, Orvida PharmaNESS ZIONA, Israel, April ...
The IMPACTS-BP trial showed that SPRINT-like reductions in systolic BP are possible even in tough real-world scenarios.
Paul R. Knight III, MD, PhD, an internationally recognized physician-scientist and former chair of the Department of Anesthesiology at the Jacobs School of Medicine and Biomedical Sciences, died March ...
Proprietary capsid engineering supports comparable cardiac gene delivery at 5–10-fold lower vector doses, potentially improving batch economics, easing purification constraints, and widening ...
Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results